Alzamend Neuro announces positive Phase IIA results for AL001; identifies MTD without need for lithium TDM

Alzamend Neuro, Inc.

Phase IIA multiple ascending dose study identified MTD of lithium carbonate equivalent 240 mg TID, unlikely to require lithium TDM.
Company plans two Phase II trials for mild-to-moderate Alzheimer's, initiated by Q1 2024.
Plans to file INDs for bipolar disorder, major depressive disorder, and PTSD by end of 2023.
CEO states data supports AL001 as next-gen lithium therapy without TDM.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.